ClinicalTrials.gg
CompletedNCT04776135Updated Jul 15, 2026Results posted

Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube

A Phase 1 interventional study of MT-1186 in Healthy Adult Subjects, sponsored by Shionogi. Completed at 1 site in Japan. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Shionogi · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Study summary

To investigate the comparative bioavailability of edaravone oral suspension administered orally and via a nasogastric tube in healthy adult subjects

02

Conditions studied

  • Healthy Adult Subjects
03

In context

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Subjects who meet all of the following criteria and who have the capability of giving will be included in the study.

  1. Healthy adult male or female volunteers
  2. Japanese
  3. Subjects aged between 20 and 45 years at the time of informed consent
  4. Subjects who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study

Exclusion Criteria: Subjects who meet any of the following criteria between screening and product administration will be excluded from the study.

  1. Subjects with a current or previous history of cardiac, hepatic, renal, gastrointestinal, respiratory, psychiatric/nervous, hematopoietic, or endocrine diseases, and those whom the investigator (or subinvestigator) deems unsuitable for the study
  2. History of drug or food allergies
  3. History of alcohol or drug abuse or dependence
  4. (BMI) of \<18.0 or >30.0, or a body weight of \<50 kg (BMI formula: body weight [kg]/height [m]2, rounded to one decimal place)
  5. Positive test for any of the following at screening: surface antigen, serological test for syphilis, virus antibody, or antigen/antibody, subject has a positive COVID-19 virus test on Day -1
  6. Any 12-lead abnormality or interval ≥450 msec
  7. Blood donation or sampling with a total volume of ≥400 mL within 12 weeks, ≥200 mL within 4 weeks, or ≥800 mL within one year before providing informed consent
  8. Blood component donation or blood sampling within 2 weeks before providing informed consent, or blood donation and transfusion from informed consent to the start of investigational product administration
  9. Subjects who have undergone any surgery known to affect the gastrointestinal absorption of drugs (except for appendectomy and herniotomy)
  10. Female subjects of who do not agree to use an effective method of from screening or 2 weeks before the start of investigational product administration, whichever comes earlier, to 14 days after the completion (or discontinuation) of investigational product administration. Male subjects who do not agree to use an effective method of contraception from the start of investigational product administration to 14 days after the completion (or discontinuation) of investigational product administration
  11. Subjects who have previously received edaravone
  12. Subjects who have participated in another clinical study and received an investigational product within 12 weeks before providing informed consent
  13. Subjects who have used any drugs other than the single use of acetylsalicylic acid within 7 days before the initiation of investigational product administration
  14. Use of alcohol or any products containing xanthin or caffeine within 24 hours before screening and visit on Day -1
  15. Use of any nutritional supplement(s) within 7 days before the initiation of investigational product administration
  16. Use of grapefruit, grapefruit juice, or any processed food(s) containing these substances within 24 hours before screening and visit on Day -1
  17. Use of any tobacco or nicotine-containing product(s) within 24 hours before screening and visit on Day -1
  18. Female subjects who have a positive pregnancy test at screening and on Day -1, are pregnant or breast feeding, or plan to get pregnant during the study
  19. Subjects with a history of reconstructive nasal surgery, or any evidence of deformities or asymmetry of the nose, non-patent nares/obstructed nasal airway, or the presence of nasal ulcers or polyps that would prevent an adequate NGT insertion.
  20. Subjects judged by the investigator (or subinvestigator) to be unsuitable for the study for any other reason
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    MT-1186 orally

    Subjects receive the edaravone oral suspension orally.

    Drug: MT-1186

  • Experimental
    MT-1186 via a nasogastric tube

    Subjects receive the edaravone oral suspension via a nasogastric tube

    Drug: MT-1186

Interventions

  • Suspension

    Also known as: Edaravone

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Versus Time Curve (AUC) of Edaravone

    Area under the plasma concentration versus time curve from time zero up to the last quantifiable concentration time-point (AUC0-t) of edaravone, and Area under the plasma concentration versus time curve from time zero up to infinity with extrapolation of the terminal phase (AUC0-inf) of edaravone.

    Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hours after administration.

  2. Maximum Plasma Concentration (Cmax) of Edaravone

    Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.

  3. Time to Reach Maximum Plasma Concentration (Tmax) of Edaravone

    Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.

  4. Terminal Elimination Half-life (t1/2) of Edaravone

    Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.

  5. Apparent Terminal Elimination Rate Constant (Kel) of Edaravone

    Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.

  6. Mean Residence Time (MRT) of Edaravone

    Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.

  7. Apparent Total Clearance (CL/F) of Edaravone

    Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.

  8. Apparent Distribution Volume at Elimination Phase (Vz/F) of Edaravone

    Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.

  9. Apparent Distribution Volume at Steady State (Vss/F) of Edaravone

    Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.

Secondary outcomes

  1. Number of Participants With Adverse Events and Adverse Drug Reactions

    Time frame: Day 1 to 11

07

Results

Posted Jan 8, 2024

Participant flow

Period 1
Participant flow — Period 1
MilestoneMT-1186 Orally, Then MT-1186 Via a Nasogastric Tube (NGT)MT-1186 Via NGT, Then MT-1186 Orally
Started1818
Completed1818
Not completed00
Period 2
Participant flow — Period 2
MilestoneMT-1186 Orally, Then MT-1186 Via a Nasogastric Tube (NGT)MT-1186 Via NGT, Then MT-1186 Orally
Started1818
Completed1818
Not completed00

Outcome measures

PrimaryArea Under the Concentration Versus Time Curve (AUC) of Edaravone

Area under the plasma concentration versus time curve from time zero up to the last quantifiable concentration time-point (AUC0-t) of edaravone, and Area under the plasma concentration versus time curve from time zero up to infinity with extrapolation of the terminal phase (AUC0-inf) of edaravone.

Time frame:
Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hours after administration.
Reported as:
Mean · ng·h/mL
Area Under the Concentration Versus Time Curve (AUC) of Edaravone
ng·h/mLMT-1186 OrallyMT-1186 Via NGT
AUC0-t2612 ± 7872592 ± 866
AUC0-inf2657 ± 8012617 ± 870
Statistical analysis
  • MT-1186 Orally vs MT-1186 Via NGT · ANOVA · Ratio (ngt/oral): 0.987 · 90% CI 0.936 to 1.041
  • MT-1186 Orally vs MT-1186 Via NGT · ANOVA · Ratio (ngt/oral): 0.981 · 90% CI 0.931 to 1.033
PrimaryMaximum Plasma Concentration (Cmax) of Edaravone
Time frame:
Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Edaravone
ng/mLMT-1186 OrallyMT-1186 Via NGT
Maximum Plasma Concentration (Cmax) of Edaravone2470 ± 839.82775 ± 1444
Statistical analysis
  • MT-1186 Orally vs MT-1186 Via NGT · ANOVA · Ratio (ngt/oral): 1.052 · 90% CI 0.903 to 1.227
PrimaryTime to Reach Maximum Plasma Concentration (Tmax) of Edaravone
Time frame:
Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Reported as:
Median · h
Time to Reach Maximum Plasma Concentration (Tmax) of Edaravone
hMT-1186 OrallyMT-1186 Via NGT
Time to Reach Maximum Plasma Concentration (Tmax) of Edaravone0.50 (0.25 to 0.50)0.25 (0.08 to 1.00)
PrimaryTerminal Elimination Half-life (t1/2) of Edaravone
Time frame:
Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Reported as:
Mean · h
Terminal Elimination Half-life (t1/2) of Edaravone
hMT-1186 OrallyMT-1186 Via NGT
Terminal Elimination Half-life (t1/2) of Edaravone21.52 ± 33.8313.53 ± 13.81
PrimaryApparent Terminal Elimination Rate Constant (Kel) of Edaravone
Time frame:
Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Reported as:
Mean · 1/h
Apparent Terminal Elimination Rate Constant (Kel) of Edaravone
1/hMT-1186 OrallyMT-1186 Via NGT
Apparent Terminal Elimination Rate Constant (Kel) of Edaravone0.06430 ± 0.037760.07713 ± 0.03269
PrimaryMean Residence Time (MRT) of Edaravone
Time frame:
Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Reported as:
Mean · h
Mean Residence Time (MRT) of Edaravone
hMT-1186 OrallyMT-1186 Via NGT
Mean Residence Time (MRT) of Edaravone4.66 ± 8.892.89 ± 1.44
PrimaryApparent Total Clearance (CL/F) of Edaravone
Time frame:
Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Reported as:
Mean · L/h
Apparent Total Clearance (CL/F) of Edaravone
L/hMT-1186 OrallyMT-1186 Via NGT
Apparent Total Clearance (CL/F) of Edaravone42.8 ± 12.343.8 ± 12.6
PrimaryApparent Distribution Volume at Elimination Phase (Vz/F) of Edaravone
Time frame:
Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Reported as:
Mean · L
Apparent Distribution Volume at Elimination Phase (Vz/F) of Edaravone
LMT-1186 OrallyMT-1186 Via NGT
Apparent Distribution Volume at Elimination Phase (Vz/F) of Edaravone1209 ± 1682816 ± 782
PrimaryApparent Distribution Volume at Steady State (Vss/F) of Edaravone
Time frame:
Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Reported as:
Mean · L
Apparent Distribution Volume at Steady State (Vss/F) of Edaravone
LMT-1186 OrallyMT-1186 Via NGT
Apparent Distribution Volume at Steady State (Vss/F) of Edaravone183.7 ± 299.9125.4 ± 67.7
SecondaryNumber of Participants With Adverse Events and Adverse Drug Reactions
Time frame:
Day 1 to 11
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Adverse Drug Reactions
ParticipantsMT-1186 OrallyMT-1186 Via NGT
Number of Participants with Adverse events13
Number of Participants with adverse drug reactions01

Adverse events

Collected over The provision of informed consent to Day 11. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MT-1186 Orally0/36 (0%)0/36 (0%)1/36 (2.8%)
MT-1186 Via NGT0/36 (0%)0/36 (0%)3/36 (8.3%)
Most frequent other events
Most frequent other events
EventMT-1186 OrallyMT-1186 Via NGT
Alanine aminotransferase increasedInvestigations0/362/36
Aspartate aminotransferase increasedInvestigations0/361/36
Blood creatine phosphokinase increasedInvestigations0/361/36
Blood creatinine increasedInvestigations1/360/36
C-reactive protein increasedInvestigations0/361/36

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MT-1186 Orally, Then MT-1186 Via a Nasogastric Tube (NGT)MT-1186 Via NGT, Then MT-1186 OrallyTotal
<=18 years000
Between 18 and 65 years181836
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)MT-1186 Orally, Then MT-1186 Via a Nasogastric Tube (NGT)MT-1186 Via NGT, Then MT-1186 OrallyTotal
Female6612
Male121224
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MT-1186 Orally, Then MT-1186 Via a Nasogastric Tube (NGT)MT-1186 Via NGT, Then MT-1186 OrallyTotal
American Indian or Alaska Native000
Asian181836
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Investigational site
    Tokyo, Toshima-ku 171-0014, Japan
09

References and documents

Publications

  • Shimizu H, Nishimura Y, Shiide Y, Ueda M, Yokota S, Kato Y, Hirai M. Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study. Clin Pharmacol Drug Dev. 2023 Jan;12(1):77-84. doi: 10.1002/cpdd.1175. Epub 2022 Oct 12. PubMed 36225132 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Apr 2021, 1 month.

Results were first posted in Jan 2024, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2021
First posted
Mar 1, 2021
StartActual
Feb 26, 2021
Primary completionActual
Apr 1, 2021
CompletionActual
Apr 16, 2021
Results first posted
Jan 8, 2024
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04776135
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Mar 1, 2021
Start date
Feb 26, 2021
Primary completion
Apr 1, 2021
Completion
Apr 16, 2021
Results posted
Jan 8, 2024
Last update
Jul 15, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion